Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tannic Acid

FDA-approved product (injectable, injection).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Tannic Acid
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Tannic Acid. Its therapeutic class is shown instead.

Anti-infective classification
Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.

Repurposing investigation

Tannic Acid reaches ≥40% AI-predicted activity against MRSA, but no WHO ATC code or FDA pharmacologic class says whether it is already an antimicrobial. It needs review, so it is not counted among the repurposing candidates.

AI-predicted activity

AI prediction · nothing measured
  • MRSA42.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis34.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tannic Acid in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tannic Acid with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Oral Vitamin B12 Supplementation and Cognitive Performance in Elderly People

    NCT00111267 · start 2003-05

    Registered record
    Registry ID
    NCT00111267
    Conditions
    Cognitive Decline; Cognitive Symptoms
    Interventions
    vitamin B12 supplementation; vitamin B12 + folic acid combined supplementation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-05
    Completion
    2005-01
    Enrolment
    165

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCognitive Decline; Cognitive Symptoms
    Interventionvitamin B12 supplementation; vitamin B12 + folic acid combined supplementation
    PhaseNot applicable
    Registry statusCompleted

  • Plasma Vitamin and Homocysteine Levels and Thrombosis in Patients With Ph-negative MPNs

    NCT01878916 · start 2003-01

    Registered record
    Registry ID
    NCT01878916
    Conditions
    Thrombosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-01
    Completion
    2004-06
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Homocysteine Study (HOST)

    NCT00032435 · start 2001-05

    Registered record
    Registry ID
    NCT00032435
    Conditions
    End Stage Renal Disease; Renal Failure
    Interventions
    PAL-40 Active; PAL-40 Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-05
    Completion
    2006-09
    Enrolment
    2,003

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease; Renal Failure
    InterventionPAL-40 Active; PAL-40 Placebo
    PhasePhase 3
    Registry statusCompleted

  • Prenatal Multi-micronutrient Supplementation and Pregnancy Outcome

    NCT00168688 · start 2001-01

    Registered record
    Registry ID
    NCT00168688
    Conditions
    Pregnancy; Birth Weight
    Interventions
    multi micronutrient supplement; MN1; MN2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-01
    Completion
    2002-10
    Enrolment
    2,100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnancy; Birth Weight
    Interventionmulti micronutrient supplement; MN1; MN2
    PhasePhase 1
    Registry statusCompleted

  • TB Nutrition, Immunology and Epidemiology

    NCT00170404 · start 2000-06

    Registered record
    Registry ID
    NCT00170404
    Conditions
    Mycobacterium Tuberculosis
    Interventions
    Folic Acid; Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.; Selenium; Vitamin A
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-06
    Completion
    2005-10
    Enrolment
    887

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Tuberculosis
    InterventionFolic Acid; Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.; Selenium; Vitamin A
    PhasePhase 3
    Registry statusCompleted